NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ENTX Stock Alerts $2.46 -0.08 (-3.15%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.26▼$2.5450-Day Range$1.37▼$2.9852-Week Range$0.52▼$3.35Volume154,644 shsAverage Volume316,644 shsMarket Capitalization$73.16 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Entera Bio alerts: Email Address Entera Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside306.5% Upside$10.00 Price TargetShort InterestHealthyDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.25) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector715th out of 921 stocksBiological Products, Except Diagnostic Industry121st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntera Bio has only been the subject of 1 research reports in the past 90 days.Read more about Entera Bio's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 60.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Entera Bio this week, compared to 0 articles on an average week.Search InterestOnly 11 people have searched for ENTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Entera Bio is held by insiders.Percentage Held by InstitutionsOnly 14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.25) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 6.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Entera Bio Stock (NASDAQ:ENTX)Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More ENTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTX Stock News HeadlinesMay 10, 2024 | investorplace.comENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024May 10, 2024 | globenewswire.comEntera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 2, 2024 | americanbankingnews.comEntera Bio (NASDAQ:ENTX) Trading Up 2%April 30, 2024 | finance.yahoo.comAre Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 8, 2024 | globenewswire.comEntera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchMarch 26, 2024 | globenewswire.comEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 23, 2024 | finance.yahoo.comWe Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business GrowthMarch 20, 2024 | globenewswire.comEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeMarch 12, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 9, 2024 | finance.yahoo.comENTX May 2024 5.000 callMarch 8, 2024 | globenewswire.comEntera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | investing.comEntera Bio regains NASDAQ compliance with bid priceMarch 4, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 4, 2024 | globenewswire.comEntera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 17, 2024 | finance.yahoo.comENTX Mar 2024 2.500 callJanuary 30, 2024 | finance.yahoo.comEntera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 20, 2024 | ca.finance.yahoo.comENTX Jan 2024 10.000 callJanuary 3, 2024 | finance.yahoo.comEntera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleDecember 31, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Short Interest ReportDecember 27, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX) Dividends: History, Yield and DatesDecember 26, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Analyst Ratings, Price Targets, PredictionsDecember 26, 2023 | finance.yahoo.comEntera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025November 29, 2023 | finance.yahoo.comInterim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformNovember 27, 2023 | msn.comEntera Bio (ENTX) Price Target Increased by 66.67% to 10.20See More Headlines Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today5/10/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+306.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax Margin-71,042.87% Return on Equity-101.78% Return on Assets-83.90% Debt Debt-to-Equity RatioN/A Current Ratio10.32 Quick Ratio10.32 Sales & Book Value Annual Sales$130,000.00 Price / Sales544.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book6.83Miscellaneous Outstanding Shares28,800,000Free FloatN/AMarket Cap$70.85 million OptionableOptionable Beta1.63 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Miranda J. Toledano M.B.A. (Age 47)CEO & Director Comp: $418kMs. Dana Yaacov-Garbeli CPA (Age 41)Chief Financial Officer Comp: $193kDr. Hillel Galitzer M.B.A. (Age 46)Ph.D., Chief Operating Officer Comp: $296kDr. Arthur C. Santora II (Age 73)M.D., Ph.D., Chief Medical Officer Comp: $355kKey CompetitorsGenenta ScienceNASDAQ:GNTACidara TherapeuticsNASDAQ:CDTXLENZ TherapeuticsNASDAQ:LENZAligos TherapeuticsNASDAQ:ALGSIkena OncologyNASDAQ:IKNAView All CompetitorsInsidersHaya TaitelBought 9,500 shares on 1/12/2024Total: $9,405.00 ($0.99/share)Haya TaitelBought 7,615 shares on 1/10/2024Total: $5,863.55 ($0.77/share)Miranda Jayne ToledanoBought 23,952 shares on 12/22/2023Total: $17,005.92 ($0.71/share)Sean EllisBought 40,000 shares on 8/21/2023Total: $24,000.00 ($0.60/share)View All Insider Transactions ENTX Stock Analysis - Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks. What is Entera Bio's stock price target for 2024? 1 Wall Street research analysts have issued 12-month price targets for Entera Bio's shares. Their ENTX share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 306.5% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts. How have ENTX shares performed in 2024? Entera Bio's stock was trading at $0.60 at the start of the year. Since then, ENTX shares have increased by 310.0% and is now trading at $2.46. View the best growth stocks for 2024 here. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) announced its earnings results on Friday, March, 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? Entera Bio (ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENTX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
